|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We therefore developed a Single Nucleotide Polymorphism (SNP) assay to evaluate allelic imbalance at the HER2/TOP2A locus in three different entities of primary breast tumors.
|
26022247 |
2015 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
We describe an approach for analyzing formalin-fixed, paraffin-embedded breast tumors on tissue microarrays with TOP2A fluorescence in situ hybridization coupled with cytokeratin immunofluorescence to target tumor cells.
|
22204715 |
2012 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
We describe an approach for analyzing formalin-fixed, paraffin-embedded breast tumors on tissue microarrays with TOP2A fluorescence in situ hybridization coupled with cytokeratin immunofluorescence to target tumor cells.
|
22204715 |
2012 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In this study, we determined TOP2A status in 61 breast tumor samples by real-time PCR, DNA microarrays, immunohistochemistry (IHC), and fluorescence in situ hybridization (FISH), and then evaluated these results with clinical-pathological features and breast cancer intrinsic subtypes.
|
21435434 |
2011 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
C-myc amplification was observed in 40% (40/100) of breast tumours, and was significantly associated with ER-negative tumours (23/40 for ER(-) versus 17/60 for ER(+), P=0.004), high histological grade tumours (11/18 for grade 3 versus 29/82 for grades 1+2, P=0.043) and TOP2A-positive tumours (28/51 for TOP2A(+) versus 12/49 for TOP2A(-), P=0.002). pCR rate was 20% for total patients (10.0% for ER(+) and 35.0% for ER(-)).
|
21741827 |
2011 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D.
|
18465341 |
2008 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines.
|
18332872 |
2008 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
HER-2, TOP2A and chromosome 17 alterations in breast cancer.
|
17922046 |
2007 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The topoisomerase IIalpha gene, TOP2A, is located adjacent to the HER-2 oncogene at the chromosome location 17q12-q21 and is either amplified or deleted (with equal frequency) in a great majority of HER-2 amplified primary breast tumors and also in tumors without HER-2 amplification.
|
17100565 |
2006 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We performed the assay for the TOP2A gene amplification and deletion on a tissue microarray (TMA) of 284 breast tumor samples from the patients treated by doxorubicin-based adjuvant chemotherapy.
|
16502015 |
2006 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer.
|
16864174 |
2006 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival.
|
16533774 |
2006 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group.
|
16234514 |
2005 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group.
|
16234514 |
2005 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Our results suggest that TOP2A gene amplification in breast tumors does not predict high expression of topoisomerase II alpha protein.
|
14978790 |
2004 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
For characterizing this region, a commercial ERBB2-containing contig probe and 7 probes prepared from single overlapping BAC and P1 clones lying telomeric to ERBB2 and including TOP2A were hybridized to 77 ERBB2-amplified archival breast tumor specimens from 75 patients.
|
15034864 |
2004 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Prognostic value of Topoisomerase II in female breast cancer.
|
15375522 |
2004 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In this issue of the Cytopathology, Bofin et al. present preliminary evidence for high prevalance of TOP2A amplification and deletion not only in the HER-2 amplified breast tumours, but also in the primary breast tumours without the HER-2 amplification.
|
14632727 |
2003 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
In this issue of the Cytopathology, Bofin et al. present preliminary evidence for high prevalance of TOP2A amplification and deletion not only in the HER-2 amplified breast tumours, but also in the primary breast tumours without the HER-2 amplification.
|
14632727 |
2003 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
|
12006526 |
2002 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide.
|
11583189 |
2001 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
We characterized the copy number aberrations of TOP2A and ERBB2 in 136 primary breast tumors by FISH.
|
10469452 |
1999 |